CY1126038T1 - Αναστολεις ακετυλοχολινεστερασης για τη θεραπεια δερματολογικων καταστασεων - Google Patents

Αναστολεις ακετυλοχολινεστερασης για τη θεραπεια δερματολογικων καταστασεων

Info

Publication number
CY1126038T1
CY1126038T1 CY20221100545T CY221100545T CY1126038T1 CY 1126038 T1 CY1126038 T1 CY 1126038T1 CY 20221100545 T CY20221100545 T CY 20221100545T CY 221100545 T CY221100545 T CY 221100545T CY 1126038 T1 CY1126038 T1 CY 1126038T1
Authority
CY
Cyprus
Prior art keywords
dermatitis
treatment
skin
acne
skin conditions
Prior art date
Application number
CY20221100545T
Other languages
English (en)
Inventor
Frank Anthony SPALLITTA
Original Assignee
Attillaps Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attillaps Holdings filed Critical Attillaps Holdings
Publication of CY1126038T1 publication Critical patent/CY1126038T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Οι τρόποι υλοποίησης της εφεύρεσης περιλαμβάνουν τη θεραπεία δερματικών παθήσεων με τοπική ή από του στόματος χρήση αναστολέα ακετυλοχολινεστεράσης. Μειώνοντας ή εξαλείφοντας αποτελεσματικά τον πληθυσμό των ακάρεων Demodex στις προσβεβλημένες περιοχές του δέρματος και στις περιοχές όπου μπορεί να υπάρχουν ακάρεα Demodex, αυτή η θεραπεία επιτυγχάνει μια πιο πλήρη ύφεση των κλινικών σημείων και συμπτωμάτων των δερματικών παθήσεων από οποιαδήποτε μέθοδο που περιγράφηκε προηγουμένως. Οι τρόποι υλοποίησης της εφεύρεσης είναι χρήσιμοι για τη θεραπεία δερματικών παθήσεων που συμπεριλαμβάνουν την κοινή ακμή, την σμηγματορροϊκή δερματίτιδα, την περιστοματική δερματίτιδα, ένα εξάνθημα σε μορφή ακμής, την παροδική ακανθολυτική δερματοπάθεια, την κεγχροειδή νεκρωτική ακμή, την ψωρίαση, την επαγόμενη από στεροειδή δερματίτιδα, την πρωτοπαθή ερεθιστική δερματίτιδα και τη ροδόχρου νόσο.
CY20221100545T 2014-06-19 2022-08-10 Αναστολεις ακετυλοχολινεστερασης για τη θεραπεια δερματολογικων καταστασεων CY1126038T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462014520P 2014-06-19 2014-06-19
PCT/US2015/036448 WO2015195928A1 (en) 2014-06-19 2015-06-18 Acetylcholinesterase inhibitors for treatment of dermatological conditions

Publications (1)

Publication Number Publication Date
CY1126038T1 true CY1126038T1 (el) 2023-11-15

Family

ID=54936099

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100545T CY1126038T1 (el) 2014-06-19 2022-08-10 Αναστολεις ακετυλοχολινεστερασης για τη θεραπεια δερματολογικων καταστασεων

Country Status (16)

Country Link
US (3) US10500183B2 (el)
EP (2) EP4088724B1 (el)
AU (1) AU2015277038B2 (el)
CA (1) CA2952838C (el)
CY (1) CY1126038T1 (el)
DK (1) DK3157534T3 (el)
ES (1) ES2925021T3 (el)
HR (1) HRP20220854T1 (el)
HU (1) HUE059303T2 (el)
LT (1) LT3157534T (el)
PL (1) PL3157534T3 (el)
PT (1) PT3157534T (el)
RS (1) RS63433B1 (el)
SI (1) SI3157534T1 (el)
WO (1) WO2015195928A1 (el)
ZA (1) ZA201700183B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2917815C (en) * 2013-07-29 2022-08-30 Attillaps Holdings Organophosphates for treating afflictions of the skin
US11446241B2 (en) * 2013-07-29 2022-09-20 Attillaps Holdings Inc. Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
WO2019126541A1 (en) * 2017-12-20 2019-06-27 Attillaps Holdings Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
HRP20220854T1 (hr) 2014-06-19 2022-10-14 Attillaps Holdings Inhibitori acetilkolinesteraze za liječenje dermatoloških stanja
EP3454855B1 (en) * 2016-05-13 2023-12-20 Delnova, Inc. Treating of side-effects resulting from chemodenervation
CN109200051A (zh) * 2017-07-03 2019-01-15 南京和博生物医药有限公司 石杉碱甲及其类似物作为治疗炎症性疾病药物的用途
BE1025705B1 (fr) 2017-09-12 2019-06-18 Cosucra Groupe Warcoing Sa Amélioration de la maladie et des conditions générales de la volaille et du bétail à l'aide d'une racine chicorée séchée
PL3723739T3 (pl) 2017-12-15 2024-09-16 Tarsus Pharmaceuticals, Inc. Preparaty izoksazolinowe i ich zastosowanie w leczeniu zapalenia powiek
WO2019136225A1 (en) * 2018-01-05 2019-07-11 Attillaps Holdings Treating dermatological conditions with chloroquine and/or hydroxychloroquine
US20210069176A1 (en) * 2018-01-05 2021-03-11 Attillaps Holdings Treating Autoimmune Disorders with Chloroquine and/or Hydroxychloroquine
WO2021102072A1 (en) * 2019-11-19 2021-05-27 Rythera Therapeutics, Inc. Composition and method for skin treatment
US20210290603A1 (en) * 2020-03-18 2021-09-23 Chemistryrx Methods for treating acne
CN114099490A (zh) * 2021-12-30 2022-03-01 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 卡巴拉汀在制备促进缺血超长随意皮瓣存活的药物的作用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
DE4217396A1 (de) 1992-05-26 1993-12-02 Bayer Ag Metrifonat enthaltendes Arzneimittel
EP1056473B8 (en) 1998-02-09 2005-07-20 Bracco International B.V. Targeted delivery of biologically active media
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6133310A (en) 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
WO2002089584A1 (en) 2001-05-09 2002-11-14 Medicis Pharmaceutical Corporation Ectoparasiticidal compositions and methods of their use
AU2003215011A1 (en) * 2002-02-08 2003-09-02 Mcneil-Ppc, Inc. Topical ivermectin composition
EP1531840B8 (en) 2002-06-19 2012-03-21 Institut de Recherche en Semiochimie et Ethologie Appliquée Allomone repulsive compositions for controlling arachnids
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US7899527B2 (en) * 2004-05-13 2011-03-01 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase
WO2006017263A1 (en) * 2004-07-12 2006-02-16 Taro Pharmaceutical Industries Ltd. Topical gel formulation comprising organophosphate insecticide and its preparation thereof
GB2419093A (en) 2004-10-12 2006-04-19 Ernir Snorrason Acetylcholinesterase inhibitors for the treatment of skin
US9186345B2 (en) * 2004-10-12 2015-11-17 Hakon Hakonarson Method of treating skin diseases
WO2006119174A1 (en) 2005-04-30 2006-11-09 Ocular Surface Center, P.A. Method for treating ocular demodex
FR2886851B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
CN101583278B (zh) 2006-09-01 2013-07-10 杜邦公司 包含茚虫威的局部外用给药制剂
US20080292560A1 (en) 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
WO2008088827A2 (en) 2007-01-16 2008-07-24 Tyratech, Inc. Pest control compositions and methods
US20130052271A1 (en) * 2011-08-29 2013-02-28 Richard S. Sternasty Compositions and Methods for Treating Pain
FR2915489B1 (fr) * 2007-04-27 2009-07-31 Univ Henri Poincare Nancy I Et Phosphotriesterases hyperthermophiles mutees et leurs utilisations
EP2337544A2 (en) * 2007-04-30 2011-06-29 Living Proof, Inc. Use of matrix metalloproteinase inhibitors in skin care
US7919522B2 (en) 2007-05-03 2011-04-05 Merial Limited Compositions comprising C-13 alkoxyether macrolide compounds and phenylpyrazole compounds
JP2010527928A (ja) 2007-05-18 2010-08-19 ヴィヴァス・インコーポレイテッド ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用
GB0713790D0 (en) 2007-07-16 2007-08-22 Nettforsk As Method
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
US8128968B2 (en) * 2007-08-29 2012-03-06 Tissuetech, Inc. Compositions and methods for treating Demodex infestations
TW200924647A (en) 2007-08-30 2009-06-16 Schering Plough Ltd Local topical administration formulations containing fipronil
DE102007043006B4 (de) 2007-09-06 2010-04-08 Freie Universität Berlin Vorrichtung und Verfahren zur Exponierung eines Insekts mit einem Wirkstoff sowie Verfahren zur Bestimmung der Wirkung eines Wirkstoffs auf ein Insekt
EP2072501A1 (en) 2007-12-21 2009-06-24 Bayer CropScience AG Aminobenzamide derivatives as useful agents for controlling animal parasites
BRPI0910937B1 (pt) 2008-04-15 2022-05-31 Lucas Meyer Cosmetics Canada Inc Composições cosméticas compreendendo exopolissacarídeos derivados de esteiras microbianas e uso das mesmas
US8247405B2 (en) 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
US9023858B2 (en) * 2010-07-23 2015-05-05 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-d]pyrimidines as delta-5-desaturase inhibitors
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
JP2014028758A (ja) 2010-11-19 2014-02-13 Nissan Chem Ind Ltd 寄生虫及び衛生害虫防除剤
WO2012135763A1 (en) 2011-03-31 2012-10-04 Agraquest, Inc. Pesticidal mixtures
FR2975004B1 (fr) * 2011-05-13 2013-06-28 Expanscience Lab Nouvel actif anti-rougeurs et compositions cosmetiques le comprenant
AR088668A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
JO3626B1 (ar) 2012-02-23 2020-08-27 Merial Inc تركيبات موضعية تحتوي على فيبرونيل و بيرميثرين و طرق استخدامها
CA2940871C (en) * 2013-03-13 2020-10-20 Genetic Disease Investigators, LLC Methods and compositions for correction of organ dysfunction
US11446241B2 (en) * 2013-07-29 2022-09-20 Attillaps Holdings Inc. Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
CA2917815C (en) 2013-07-29 2022-08-30 Attillaps Holdings Organophosphates for treating afflictions of the skin
HRP20220854T1 (hr) * 2014-06-19 2022-10-14 Attillaps Holdings Inhibitori acetilkolinesteraze za liječenje dermatoloških stanja

Also Published As

Publication number Publication date
EP4088724B1 (en) 2024-10-23
US11045442B2 (en) 2021-06-29
AU2015277038B2 (en) 2020-09-17
SI3157534T1 (sl) 2022-08-31
US20170135978A1 (en) 2017-05-18
EP3157534A1 (en) 2017-04-26
HUE059303T2 (hu) 2022-11-28
AU2015277038A1 (en) 2017-02-02
WO2015195928A1 (en) 2015-12-23
RS63433B1 (sr) 2022-08-31
LT3157534T (lt) 2022-09-12
US20220096420A1 (en) 2022-03-31
HRP20220854T1 (hr) 2022-10-14
ES2925021T3 (es) 2022-10-13
PL3157534T3 (pl) 2022-09-12
DK3157534T3 (da) 2022-08-22
US20200281885A1 (en) 2020-09-10
EP3157534A4 (en) 2018-03-14
EP4088724A1 (en) 2022-11-16
CA2952838A1 (en) 2015-12-23
EP3157534B1 (en) 2022-07-06
US10500183B2 (en) 2019-12-10
PT3157534T (pt) 2022-08-04
ZA201700183B (en) 2020-05-27
CA2952838C (en) 2023-09-05

Similar Documents

Publication Publication Date Title
CY1126038T1 (el) Αναστολεις ακετυλοχολινεστερασης για τη θεραπεια δερματολογικων καταστασεων
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CL2018001899A1 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)
CO2017003833A2 (es) Pirimidinonas como inhibidores del factor xia
BR112018010464A2 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
GT201600123A (es) Inhibidores de syk
CO2017001152A2 (es) Espirocicloheptanos como inhibidores de la cinasa rho (rock)
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
ECSP17064695A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CU24410B1 (es) Benzimidazol-2-aminas como inhibidores de midh1
CR20150633A (es) Derivados del bipirazol como inhibidores jak
CR20150517A (es) Inhibidores de la phd de 6-(5-hidroxi-1h-pirazol-1-il) nicotinamida
UY35971A (es) Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
BR112017027332A2 (pt) composições tópicas que compreendem um corticosteróide e um retinóide para tratar psoríase.
AR097481A1 (es) Cocristales energéticos para el tratamiento de una formación subterránea
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
BR112016025396A2 (pt) derivados de heterociclil-butanamida
ECSP17010238A (es) Compuestos novedosos de pirimidina sustituidos
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
BR112016001645A2 (pt) derivados de oxoquinazolinil-butanamida
CU20150094A7 (es) Imidazopiridazinas sustituídas